Rambaldi A, Attuati V, Bassan R, Neonato M G, Viero P, Battista R, Di Bona E, Rossi G, Pogliani E, Ruggeri M, Amaru R, Rivolta A, Giudici G, Biondi A, Barbui T
Ospedali Riuniti di Bergamo, Universita di Milano, Italy.
Leuk Lymphoma. 1996 May;21(5-6):457-66. doi: 10.3109/10428199609093444.
Over a time period of five years leukemic blast samples from 141 consecutive patients with adult ALL were referred to our laboratory, for molecular evaluation of chromosome abnormalities. The t(9;22), t(4;11) and t(1;19) which are most commonly found in adult ALL with a B-precursor phenotype were molecularly analyzed by similar RT-PCR based protocols. BCR-ABL transcripts generated by the t(9;22) translocation were demonstrated in 36 patients (25%) and were restricted to the 109 patients with B precursor ALL (33% of this group). Of 83 patients showing a, common phenotype (CD10+), 34 were BCR-ABL positive (41%) whereas only 2 out of 26 with Null ALL (HLADr+, CD19+, CD10) were positive. Interestingly, the percent of BCR-ABL positive CD1O+ ALL increases significantly with age being 20% in patients less than 30 years old and more than 50% in older patients. None of the T-ALL (24 patients) and B-ALL (8 patients) were positive. The majority of cases (67%) showed the p190 gene subtype. The cytogenetic diagnosis of Philadelphia chromosome was always confirmed by the molecular analysis and this approach allowed for the detection of the presence of the BCR-ABL rearrangement in 26 patients when a negative result or no metaphases were obtained. The complete remission rate was similar among BCR-ABL positive and negative patients but a shorter remission duration was observed in those showing molecular evidence of t(9;22) and this finding was significantly evident in CD1O+ ALL patients. By means of comparison, in most of the same adult ALL patients, we analyzed the yet unrecognized prevalence of the t(4;11) and t(1;19) translocations by the molecular analysis of their chromosomal breakpoints. Rearrangements of the ALL-1 gene on 11q23 band and ALL- l1AF.4 fusion transcripts specific for the t(4;11) were demonstrated in 7 out of the 21 Null ALL investigated, with no additional positive cases found among the other ALL subgroups. Overall the clinical behavior of t(4; 11) positive patients was dismal with a very short CR duration. Chimeric E2A-PBX1 transcripts generated by the t(1;19) were found in only two of the 87 B-precursor ALL analyzed. The presented results provide further evidence for the utility of RT-PCR based methods for the molecular diagnosis of chromosome translocations in ALL. The identification of such abnormalities can significantly contribute to the identification of more appropriate therapeutic options for standard and high risk ALL patients
在五年的时间里,我们实验室接收了141例连续性成年急性淋巴细胞白血病(ALL)患者的白血病原始细胞样本,用于染色体异常的分子评估。对成人B前体表型ALL中最常见的t(9;22)、t(4;11)和t(1;19)采用基于相似逆转录聚合酶链反应(RT-PCR)的方案进行分子分析。由t(9;22)易位产生的BCR-ABL转录本在36例患者(25%)中被检测到,且仅限于109例B前体ALL患者(占该组的33%)。在83例具有常见表型(CD10+)的患者中,34例BCR-ABL阳性(41%),而在26例无表型ALL(HLADr+、CD19+、CD10)患者中只有2例阳性。有趣的是,BCR-ABL阳性的CD1O+ ALL的百分比随年龄显著增加,小于30岁的患者中为20%,而老年患者中超过50%。所有T-ALL(24例)和B-ALL(8例)均为阴性。大多数病例(67%)显示p190基因亚型。费城染色体的细胞遗传学诊断总是通过分子分析得到证实,当获得阴性结果或无中期分裂相时,这种方法可检测到26例患者中存在BCR-ABL重排。BCR-ABL阳性和阴性患者的完全缓解率相似,但在那些有t(9;22)分子证据的患者中观察到缓解期较短,这一发现在CD1O+ ALL患者中尤为明显。通过比较,在大多数相同的成年ALL患者中,我们通过对其染色体断点的分子分析来分析尚未被认识到的t(4;11)和t(1;19)易位的发生率。在21例被研究的无表型ALL中,有7例显示11q23带的ALL-1基因重排以及t(4;11)特异 的ALL- l1AF.4融合转录本,在其他ALL亚组中未发现额外的阳性病例。总体而言,t(4; 11)阳性患者的临床行为较差,缓解期非常短。在87例被分析的B前体ALL中,只有2例发现由t(1;19)产生的嵌合E2A-PBX1转录本。所呈现的结果为基于RT-PCR的方法在ALL染色体易位分子诊断中的实用性提供了进一步证据。识别此类异常可显著有助于为标准和高危ALL患者确定更合适的治疗方案